Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Energy & FMCG, major gainers
Tue, 18 Mar 01:30 pm

Indian share markets remained buoyant in the post-noon trading session. Majority of the sectoral indices are trading in the green with energy, FMCG and metal being the biggest gainers. Only IT, realty and capital goods stocks are trading in the red.

BSE-Sensex is up 81 points and NSE-Nifty is trading 19 points up. BSE Mid Cap is trading 0.9% up and BSE Small Cap index is trading up by 0.8%. The rupee is trading at 61.0 to the US dollar.

Software stocks are trading on a mixed note with Moser Baer and Mphasis being the biggest gainers whereas HCL Infosys and Wipro are the major losers. As per a leading financial daily, Wipro is extending from being a mere application developer to a one-stop shop for customers in the US. The outsourcing industry in India has traditionally focused on application development and maintenance that garners more than 60% of the sector revenues. Wipro's system integrator model has been successful in India and the company wants to extend the model globally. As per the company, it wants to sell software, hardware as well as implement and roll it out. The systems integrator unit of Wipro has implemented core banking software for 10 Indian banks and built back offices for two telecom companies. Revenues from this unit contribute 9% to the company's overall revenues. Wipro's stock is trading down 1.8%.

Food stocks are trading mixed with ITC and VST Inds being the biggest gainers whereas Godfrey Phillips and Ruchi Soya are the major losers. As per a leading financial daily, Maharashtra Food and Drug Administration (FDA) has sent a notice to Glaxo SmithKline Consumer Healthcare (GSKCH) for overcharging on the fever & pain medicine Crocin and stopped its supplies in retail chemist shops. The price of paracetamol is fixed at Rs 9.40 for a 10-tablet strip as per the Drug Price Control Order (2013). However as per GSKCH, its drug Crocin Advance is its local invention and therefore should be exempted from price control. Crocin Advance is currently being sold at Rs 20 a strip. Additionally, FDA has also written to the National Pharmaceutical Pricing Authority (NPPA) for greater clarity on the issue. If NPPA goes in agreement with Maharashtra FDA, then other States may follow suit and stop Crocin Advance from being sold at the current price. GSKCH earns margins on distribution of Eno, Crocin and Sensodyne brands. This auxilllary income is less than 5% of the company's overall revenues. GSKCH's stock is currently trading up by 1.3%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Energy & FMCG, major gainers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.